ArticleEpilepsy & behavior reports2025
Modified Atkins Diet therapy during pregnancy for refractory idiopathic generalized epilepsy.
Article in Epilepsy & behavior reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of refractory epilepsy in pregnancy is challenging, and diet therapy has been rarely reported. We report a case of a 25-year-old woman with refractory idiopathic generalized epilepsy who achieved prolonged seizure freedom with the Modified Atkins Diet (MAD) during pregnancy. Her epilepsy began at age 3, with seizures occurring every two months despite multiple antiseizure medications and vagus nerve stimulation. Three months before her first pregnancy, MAD was initiated with a carbohydrate limit of 30 g daily, resulting in immediate seizure freedom. During the pregnancy, carbohydrate intake was gradually increased to 60-70 g daily to support fetal growth. She remained seizure-free for 10 months before experiencing breakthrough seizures in the third trimester. Oligohydramnios was subsequently detected, and she underwent induction of labor with vaginal delivery at 37 weeks. After delivery, she discontinued MAD for breastfeeding and remained seizure-free for 13 months. In her second pregnancy without MAD, she experienced two breakthrough seizures in the second trimester. She later achieved 23 months of seizure freedom. Both children have met developmental milestones appropriately. This case adds to the limited literature on diet therapy in pregnancy and is, to our knowledge, the first involving generalized epilepsy. The case suggests MAD may provide seizure control during pregnancy, even with possible sustained benefit after discontinuation. However, given the occurrence of oligohydramnios and limited safety data, larger studies are needed to clarify the efficacy, safety, and long-term outcomes of diet therapy during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.